View Single Post
  #6  
Old Thu Apr 22, 2010, 11:40 PM
Neil Cuadra Neil Cuadra is offline
Owner
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 2,553
What's surprising about the "Azacitidine and Decitabine" article is how many questions still can't be answered:
  • Would decitabine have a more significant benefit if it was tested under a different protocol?
  • What should change?: days per cycle, inpatient vs. outpatient, number of cycles.
  • Why were the M.D. Anderson results different?
  • Which lower-risk MDS patients should receive the drugs?
  • If so, how soon should their treatment begin?
  • How long should drug therapy continue if there is no response?
We're certainly keeping the researchers busy. In the meantime, doctors make treatment decisions based on all available information.
Reply With Quote